vaccinex.com - VCNX Income before deduction of interest, taxes and amortization

Graphic logo of Vaccinex Inc. (VCNX)

Monthly EBITDA dynamics on the current GURU.Markets platform chart demonstrate Vaccinex, Inc. (VCNX) dependence on external financing and partnership tranches. Capitalization relies on the development of antibodies against cancer and Huntington's disease. However, geopolitical tensions are hindering international trials and patent protection. Within this structure, the metric serves as the target level for assessing the business's operational efficiency.

Profit before payment of interest, taxes and amortization: Vaccinex, Inc. (VCNX) for 07/04/2022 - 11/11/2026

Vaccinex - analytical breakdowns and key metrics (VCNX)

- market value and analyst target forecast:
Market Price Vaccinex Inc|VCNX - Consensus Target
- issuer market value details:
Market Value Vaccinex|VCNX - Enterprise Value
- book capitalization information:
Net Assets per Share Vaccinex|VCNX - Company Book Value|Market Cap to Net Assets Ratio vaccinex.com|VCNX - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Vaccinex, Inc.|VCNX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Vaccinex Inc.|VCNX - Company Debts|Debt to Book Value Ratio Vaccinex|VCNX - Company Long-Term Debt|Short-Term Debt Vaccinex|Critical Liquidity vaccinex.com
- company profitability and valuation multiples indicators:
VCNX - Net Income|Future Net Profit Vaccinex, Inc.|VCNX - P/E Multiple|Future Price to Earnings Multiple vaccinex.com|VCNX - PEG Multiple|Company Value to EBITDA Vaccinex|VCNX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Vaccinex|VCNX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth vaccinex.com|VCNX - Earnings per share growth in current year|Net earnings per share change forecast for next year Vaccinex, Inc.
Analysis of all company metrics:Vaccinex Inc - VCNX
Mass-produced product of Vaccinex

As a developer of immunotherapy dependent on global scientific collaboration, Vaccinex, Inc. (VCNX) is exposed to the risks of clinical trial disruptions due to geopolitics. This metric measures the actual cash flow from core operations before taxes and interest, excluding accounting adjustments to assess the true value of the business. Investors should analyze the history of operating cash flow to filter out one-time anomalies and confirm revenue sustainability.

Competitors of Vaccinex, Inc. (VCNX)

NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (Innate Pharma S.A) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization INKT (MiNK)|Company profit before taxes, interest and amortization HOWL|Operating profit EBITDA IMMX (Immix Biopharma)|Income before deduction of interest, taxes and amortization ALXO|Cue Biopharma, Inc. - Operating profit EBITDA|Profit before interest, taxes and amortization PDS Biotechnology|sonnetbio.com (SONN) - Profit before payment of interest, taxes and amortization|MAIA Bio - Income before deduction of interest, taxes and amortization|LIMN (Liminatus Pharma) - Operating profit EBITDA|Operating profit EBITDA Lava Tx|Profit before payment of interest, taxes and amortization NextCure (NXTC)|LPTX: Profit before deduction of interest, taxes, depreciation and amortization|Intensity Therapeutics, Inc. - Operating profit before deduction of amortization|Sensei Biotherapeutics Inc (SNSE) - Profit before interest, taxes and amortization|TOVX: Operating profit before deduction of amortization|GRTS: Profit before payment of interest, taxes and amortization|KA: Operating profit EBITDA|NexImmune Inc (NEXI) - Operating profit EBITDA|TSBX (Turnstone Biologics Corp) - Operating profit EBITDA|Operating profit before deduction of amortization Harpoon Therapeutics Corp (HARP)